Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Keryx Biopharmaceuticals    KERX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Keryx Biopharmaceuticals : Traders Favorite: Keryx Biopharmaceuticals, McDonald's Corporation, Merck & Co, Hertz Global Holdings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/22/2013 | 08:05pm CET

NEW YORK, April 22, 2013 -Bestdarnpennystocks.com, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on Keryx Biopharmaceuticals, McDonald's Corporation, Merck & Co, Hertz Global Holdings.

Keryx Biopharmaceuticals (NASDAQ:KERX) shares gained 5.48% to $8.47. The company, on March 11, announced its results for the fourth quarter and year ended December 31, 2012. The net loss for the 4th quarter ended December 31, 2012 was $6.6 million, or $0.09 per share versus $8.4 million for quarter 2011, representing a decrease of $1.8 million and Net loss for the year ended December 31, 2012, was $22.7 million versus $28.1 million for the year ended December 31, 2011, representing a decrease in net loss of $5.4 million.

At December 31, 2012, the Company had cash, cash equivalents, interest receivable, and investment securities of $14.7 million, as compared to $39.5 million at December 31, 2011.

Has KERX Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=KERX (OR Just copy and paste the link)

McDonald's Corporation(NYSE:MCD) shares decreased 1.13% to $98.80. The company, on April 19, posted first-quarter profit that was little changed as same-store sales dropped in the U.S. for the first time since 2003 amid soft global demand. Net income was about $1.27 billion, or $1.26 share, compared with $1.27 billion, or $1.23, a year earlier. Analysts projected $1.26, the average of 29 estimates compiled by analyst.

Has MCD Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=MCD (OR Just copy and paste the link)

Additionally, MCD?s stock had its ?buy? rating restated by analysts at Janney Montgomery Scott in a research report issued to clients and investors on April 16. They currently have a $115.00 price target on the stock.

Merck & Co., Inc.(NYSE:MRK) shares fell 0.38% to $47.31. The company, on April 1st reported that it will hold its first-quarter 2013 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Wednesday, May 1.

Has MRK Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=MRK (OR Just copy and paste the link)

Additionally, the company, on April 10, announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration (FDA).

Hertz Global Holdings, Inc. (NYSE:HTZ) shares decreased 0.76% to $23.54. The company, on April 16, agreed to acquire a 20% stake in Beijing-based China Auto Rental Holdings Inc. to expand its presence in China's car-rental market. Financial terms weren't disclosed.

How Should Investors Trade HTZ Now? Get Free Trend Analysis Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=HTZ (OR Just copy and paste the link)

Additionally, the company, on April 8, announced that its wholly-owned subsidiary, The Hertz Corporation ("Hertz"), has successfully completed a repricing of its currently outstanding $1,372 billion senior secured tranche B term loan facility. As part of the repricing, the tranche B term loans will be replaced by new tranche B-2 term loans.

About bestdarnpennystocks.com
bestdarnpennystocks.com?s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by bestdarnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. bestdarnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in bestdarnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
Contacts:
bestdarnpennystocks.com
1419 Westwood Blvd Los Angeles, CA
90024-4911
staff@bestdarnpennystocks.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on KERYX BIOPHARMACEUTICALS
02:32p Keryx Biopharmaceuticals to Webcast its Presentations at Two Investor Confere..
02/16 Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Y..
02/08 Keryx Biopharmaceuticals to Webcast its Presentation at RBC Capital Markets' ..
01/12 ROBBINS ARROYO LLP : Keryx Biopharmaceuticals, Inc. KERX Misled Shareholders Acc..
01/12 Keryx Biopharmaceuticals Announces Publication of Auryxia® (ferric citrate) P..
01/09 KERYX BIOPHARMACEUTICALS INC : Results of Operations and Financial Condition, Ch..
01/09 Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corpo..
01/05 ROBBINS ARROYO LLP : Keryx Biopharmaceuticals, Inc. (KERX) Misled Shareholders A..
2016 Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgan’s 3..
2016 KERYX BIOPHARMACEUTICALS : Announces Case Study Data of Auryxia® Presented at AS..
More news
Sector news : Bio Therapeutic Drugs
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
02/16 Ardelyx Runs Towards Next Phase With Tenapanor
02/16 Tracking Seth Klarman's Baupost Group Holdings - Q4 2016 Update
02/13 Tracking David Abrams' Abrams Capital Management Portfolio - Q4 2016 Update
01/23 WEEK 4 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge
01/11 Keryx Biopharmaceuticals (KERX) Presents At 35th Annual J.P. Morgan Healthcar..
Advertisement
Financials ($)
Sales 2016 30,9 M
EBIT 2016 -109 M
Net income 2016 -154 M
Finance 2016 68,0 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 14,1x
EV / Sales 2017 7,46x
Capitalization 505 M
More Financials
Chart KERYX BIOPHARMACEUTICALS
Duration : Period :
Keryx Biopharmaceuticals Technical Analysis Chart | KERX | US4925151015 | 4-Traders
Full-screen chart
Technical analysis trends KERYX BIOPHARMACE...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 7,21 $
Spread / Average Target 51%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gregory P. Madison Chief Executive Officer & Director
John P. Butler Chairman
Christine A. Carberry Chief Operating Officer & Senior Vice President
Scott A. Holmes Chief Financial Officer & Senior Vice President
John F. Neylan Chief Medical Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
KERYX BIOPHARMACEUTICA..-14.85%505
AMGEN, INC.18.42%127 119
CELGENE CORPORATION3.19%92 788
GILEAD SCIENCES, INC.-3.24%90 681
REGENERON PHARMACEUTIC..1.23%39 273
ACTELION LTD22.45%28 907
More Results